After years of little progress in the field of schizophrenia drug treatment, Bristol Myers Squibb’s $14 billion acquisition of Karuna Therapeutics has paid off with the approval of a groundbreaking new drug. BMS’s novel medication, KarXT—now named COBENFY—received significant FDA approval on 26 September 2024 for the treatment of adults with schizophrenia. COBENFY is the first muscarinic agonist approved for schizophrenia, marking the first new treatment class for the condition since the FDA approved CLOZARIL (clozapine) 35 years ago.
Schizophrenia is a severe mental illness that impacts thinking, emotions, decision-making, and social interaction. Onset typically o...
